Kadmon (NYSE:KDMN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday. The firm currently has a $4.25 price objective on the stock. Zacks Investment Research‘s target price suggests a potential upside of 0.47% from the company’s current price.

According to Zacks, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. “

A number of other brokerages have also commented on KDMN. WBB Securities lowered Kadmon from a “hold” rating to a “sell” rating and set a $3.00 price objective for the company. in a research report on Monday, October 9th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Kadmon in a research report on Friday, November 17th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $8.65.

Shares of Kadmon (NYSE:KDMN) opened at $4.23 on Friday. The company has a market capitalization of $332.66, a PE ratio of -2.42 and a beta of 2.54. Kadmon has a 12-month low of $2.05 and a 12-month high of $5.07.

Kadmon (NYSE:KDMN) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.04). The company had revenue of $2.28 million during the quarter, compared to analysts’ expectations of $5.69 million. The firm’s revenue for the quarter was down 60.0% on a year-over-year basis. During the same period last year, the firm posted ($4.24) EPS. equities research analysts expect that Kadmon will post -1.61 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. Crestline Management LP bought a new position in Kadmon during the third quarter worth about $2,011,000. Sabby Management LLC bought a new position in Kadmon during the second quarter worth about $2,112,000. AE Wealth Management LLC boosted its holdings in Kadmon by 33.6% during the third quarter. AE Wealth Management LLC now owns 323,161 shares of the company’s stock worth $1,083,000 after buying an additional 81,226 shares during the last quarter. Sphera Funds Management LTD. bought a new position in Kadmon during the third quarter worth about $3,685,000. Finally, Vanguard Group Inc. boosted its holdings in Kadmon by 166.0% during the second quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock worth $5,870,000 after buying an additional 941,549 shares during the last quarter. Hedge funds and other institutional investors own 51.90% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/kadmon-kdmn-upgraded-by-zacks-investment-research-to-buy/1806933.html.

Kadmon Company Profile

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.